Literature DB >> 8542596

Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro.

M Yamamoto1, S Mohanam, R Sawaya, G N Fuller, M Seiki, H Sato, Z L Gokaslan, L A Liotta, G L Nicolson, J S Rao.   

Abstract

In this study, we investigated the expression of activated gelatinase A and membrane-type metalloproteinase (MT-MMP) induced by concanavalin A (ConA) in four highly invasive glioma cell lines (UWR2, UWR3, U251MG, and SNB-19). We also examined gelatinase A and MT-MMP expression in human brain tumor tissues in vivo. Gelatin zymography showed that all four cell lines expressed latent progelatinase A (M(r) 66,000). Activated gelatinase A (M(r) 62,000) was induced by ConA in only UWR2 or UWR3 cells. MT-MMP mRNA was present in all four cell lines prior to ConA treatment, and the relative hybridization signals were 1, 0.80, 0.25, and 0.15 in UWR2, UWR3, U251MG, and SNB-19 cells, respectively. These mRNA signals were dramatically increased (2,8-, 5.4-, and 2.2-fold in UWR2, UWR3, and U251MG cells, respectively) following ConA treatment; however, MT-MMP mRNA expression was unchanged in SNB-19 cells. MT-MMP protein was detected in various amounts in the four cell lines, but only after ConA pretreatment. The amount of MT-MMP mRNA was unchanged in SNB-19 after ConA treatment, and the MT-MMP mRNA level in ConA-treated U251MG was lower than in UWR2 and UWR3 without ConA treatment. MT-MMP protein was detected in SNB-19 and U251 cell lines only after ConA treatment. Gelatin zymography of human brain tumor tissues revealed that almost all samples examined contained a latent form of gelatinase A, whereas the activated form of gelatinase A was only seen in metastatic lung adenocarcinomas and malignant astrocytomas, and especially in glioblastomas. MT-MMP mRNA levels were significantly higher in malignant astrocytomas than in low-grade gliomas and normal brain tissues. These results were confirmed by PCR analysis, which showed that MT-MMP mRNA was absent or barely detectable in normal brain white matter but was easily detectable in malignant astrocytomas. Immunohistochemistry of MT-MMP in frozen sections showed that MT-MMP was localized in neoplastic astrocytes of malignant astrocytomas but was undetectable in normal white brain matter. The data indicate that MT-MMP is present in malignant human glial tumors and that MT-MMP expression correlates with expression and activation of gelatinase A during malignant progression in vivo. A direct correlation between the levels of MT-MMP protein and its transcripts was not found in vitro, suggesting that MT-MMP expression in glioma cell lines might be regulated either at the level of transcription message stability or at posttranscription. Altered MT-MMP expression might contribute, in part, to gelatinase A activation, which in turn facilitates invasion of these tumors.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8542596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

2.  MMP-9 secretion and MMP-2 activation distinguish invasive and metastatic sublines of a mouse mammary carcinoma system showing epithelial-mesenchymal transition traits.

Authors:  A M Tester; N Ruangpanit; R L Anderson; E W Thompson
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

3.  Invasiveness of hepatocellular carcinoma cell lines: contribution of membrane-type 1 matrix metalloproteinase.

Authors:  K Murakami; R Sakukawa; T Ikeda; T Matsuura; S Hasumura; S Nagamori; Y Yamada; I Saiki
Journal:  Neoplasia       Date:  1999-11       Impact factor: 5.715

4.  Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: a relationship among efficacy, joint toxicity and anticonvulsant status.

Authors:  Morris D Groves; Vinay K Puduvalli; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Kurt Jaeckle; Vivien Liu; Kenneth R Hess; Kenneth D Aldape; Victor A Levin
Journal:  J Neurooncol       Date:  2006-04-25       Impact factor: 4.130

Review 5.  Zinc and zinc-containing biomolecules in childhood brain tumors.

Authors:  Jan Hrabeta; Tomas Eckschlager; Marie Stiborova; Zbynek Heger; Sona Krizkova; Vojtech Adam
Journal:  J Mol Med (Berl)       Date:  2016-09-16       Impact factor: 4.599

6.  A novel method to establish microglia-free astrocyte cultures: comparison of matrix metalloproteinase expression profiles in pure cultures of astrocytes and microglia.

Authors:  Stephen J Crocker; Ricardo F Frausto; J Lindsay Whitton; Richard Milner
Journal:  Glia       Date:  2008-08-15       Impact factor: 7.452

7.  Unstimulated human acute myelogenous leukemia blasts secrete matrix metalloproteinases.

Authors:  A Matsuzaki; A Janowska-Wieczorek
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

8.  Association of fibroblastoid features with the invasive phenotype in human bronchial cancer cell lines.

Authors:  M Polette; C Gilles; S de Bentzmann; D Gruenert; J M Tournier; P Birembaut
Journal:  Clin Exp Metastasis       Date:  1998-02       Impact factor: 5.150

9.  Initial contact of glioblastoma cells with existing normal brain endothelial cells strengthen the barrier function via fibroblast growth factor 2 secretion: a new in vitro blood-brain barrier model.

Authors:  Keisuke Toyoda; Kunihiko Tanaka; Shinsuke Nakagawa; Dinh Ha Duy Thuy; Kenta Ujifuku; Kensaku Kamada; Kentaro Hayashi; Takayuki Matsuo; Izumi Nagata; Masami Niwa
Journal:  Cell Mol Neurobiol       Date:  2013-02-06       Impact factor: 5.046

10.  Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors.

Authors:  K Lampert; U Machein; M R Machein; W Conca; H H Peter; B Volk
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.